A statement from the Huntington’s Disease Society of America

New York, NY, February 21, 2014 — The Huntington’s Disease Society of America (HDSA) is pleased to announce its endorsement of the Enroll-HD prospective registry study, a global effort to collect a common set of clinical data and biological samples that will help scientists better understand the disease and support both the recruitment and conduct of clinical trials of potential new therapeutics for HD. Additionally, data collected from Enroll-HD will also help inform the standards of medical care for HD families. Continue reading →

New York, NY, February 21 2014 – CHDI Foundation, Inc. and Genzyme Corporation have entered into a collaboration to develop adeno-associated virus delivery of a novel gene silencing therapeutic approach for Huntington’s disease. The agreed research plan encompasses the development of a therapeutic clinical candidate that will aim to lower huntingtin protein expression, as well as the preparation and filing of an investigational new drug application with one or more regulatory authorities for an initial clinical appraisal. Continue reading →